Table 2.
Variables contributing to the variance in cost, evaluated from 2013 to 2015. The direction of variations due to variables’ contribution is shown in the profiles of Figure 3.
| Population evaluated Variables excluded | MODEL 1 Entire cohort None | MODEL 2 Entire cohort Months without HCC, Hospitalisations |
|---|---|---|
| Variables | ||
| Number of months without HCC | 43% | - |
| Hospitalisation (presence/absence) | 29% | - |
| Number of comorbidities | 12% | 34% |
| Treatment duration coverage (in months) | 10% | 20% |
| Number of infections | 3% | 14% |
| Type of first prescribed treatment (mono/bi/triple/ quadruple therapies) | - | 14% |
| Number of ED visits | - | 5% |
| 6-month gap in HCC (presence) | - | 4% |
| Booster (pharmacokinetic enhancers) as part of first-line therapy | 2% | - |
| Number of treatment changes | <1% | - |
| Age at inclusion | <1% | - |
| Number of switches between triple therapies | <1% | 4% |
| Year HIV diagnosed | <1% | <1% |
| Day hospitalisation | <1% | - |
ED, Emergency Department; HCC, HealthCare Consumption; HIV, human immunodeficiency virus.